Leuko was founded with the mission to revolutionize health management through non-invasive medical devices. The company focuses on developing innovative solutions for white blood cell (WBC) monitoring, crucial for patients undergoing chemotherapy and those at risk of life-threatening infections. Their flagship product, PointCheck™, is a fast, portable, and user-friendly device that allows frequent WBC assessments without the need for blood draws, aiming to enhance the quality of life and clinical outcomes for immunosuppressed patients worldwide.
Leuko has attracted notable attention from investors and healthcare professionals due to its groundbreaking technology. While the device is still investigational and not yet available for sale, it has the potential to significantly impact patient care by enabling more frequent and less invasive monitoring. This innovation positions Leuko as a key player in the medical device industry, with the promise of transforming how white blood cell counts are managed globally.
